Use of Human Tissue to Assess the Oncogenic Activity of Melanoma-associated Mutations

Overview

Journal Nat Genet

Specialty Genetics

Date 2005 Jun 14

PMID 15951821

Citations 64

Authors

Yakov Chudnovsky

Amy E Adams

Paul B Robbins

Qun Lin

Paul A Khavari

Affiliations

Soon will be listed here.

Abstract

Multiple genetic alterations occur in melanoma, a lethal skin malignancy of increasing incidence. These include mutations that activate Ras and two of its effector cascades, Raf and phosphoinositide 3-kinase (PI3K). Induction of Ras and Raf can be caused by active N-Ras and B-Raf mutants as well as by gene amplification. Activation of PI3K pathway components occurs by PTEN loss and by AKT3 amplification. Melanomas also commonly show impairment of the p16(INK4A)-CDK4-Rb and ARF-HDM2-p53 tumor suppressor pathways. CDKN2A mutations can produce p16(INK4A) and ARF protein loss. Rb bypass can also occur through activating CDK4 mutations as well as by CDK4 amplification. In addition to ARF deletion, p53 pathway disruption can result from dominant negative TP53 mutations. TERT amplification also occurs in melanoma. The extent to which these mutations can induce human melanocytic neoplasia is unknown. Here we characterize pathways sufficient to generate human melanocytic neoplasia and show that genetically altered human tissue facilitates functional analysis of mutations observed in human tumors.

Citing Articles

Leveraging genome-wide association studies to better understand the etiology of cancers.

Sonehara K, Okada Y Cancer Sci. 2024; 116(2):288-296.

PMID: 39561785 PMC: 11786324. DOI: 10.1111/cas.16402.

Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy.

Lang Y, Lyu Y, Tan Y, Hu Z Front Immunol. 2023; 14:1195194.

PMID: 37646021 PMC: 10461088. DOI: 10.3389/fimmu.2023.1195194.

Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer.

Barger C, Suwala A, Soczek K, Wang A, Kim M, Hong C Nat Commun. 2022; 13(1):5430.

PMID: 36114166 PMC: 9481613. DOI: 10.1038/s41467-022-33099-x.

Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling.

Doepner M, Lee I, Natale C, Brathwaite R, Venkat S, Kim S Sci Adv. 2022; 8(35):eabn4007.

PMID: 36054350 PMC: 10848963. DOI: 10.1126/sciadv.abn4007.

Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape.

Battaglia L, Scomparin A, Dianzani C, Milla P, Muntoni E, Arpicco S Pharmaceutics. 2021; 13(10).

PMID: 34683910 PMC: 8540596. DOI: 10.3390/pharmaceutics13101617.

References

Weitzman J, Yaniv M . Rebuilding the road to cancer. Nature. 1999; 400(6743):401-2. DOI: 10.1038/22637. View

Gilchrest B, Eller M, Geller A, Yaar M . The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med. 1999; 340(17):1341-8. DOI: 10.1056/NEJM199904293401707. View

Hsu M, Andl T, Li G, Meinkoth J, Herlyn M . Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci. 2000; 113 ( Pt 9):1535-42. DOI: 10.1242/jcs.113.9.1535. View

Clark E, Golub T, Lander E, Hynes R . Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000; 406(6795):532-5. DOI: 10.1038/35020106. View

Randerson-Moor J, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J . A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet. 2001; 10(1):55-62. DOI: 10.1093/hmg/10.1.55. View

Nishimura E, Jordan S, Oshima H, Yoshida H, Osawa M, Moriyama M . Dominant role of the niche in melanocyte stem-cell fate determination. Nature. 2002; 416(6883):854-60. DOI: 10.1038/416854a. View

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

Hamad N, Elconin J, Karnoub A, Bai W, Rich J, Abraham R . Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 2002; 16(16):2045-57. PMC: 186434. DOI: 10.1101/gad.993902. View

Lazarov M, Kubo Y, Cai T, Dajee M, Tarutani M, Lin Q . CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med. 2002; 8(10):1105-14. DOI: 10.1038/nm779. View

10.

Stewart S, Hahn W, OConnor B, Banner E, Lundberg A, Modha P . Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A. 2002; 99(20):12606-11. PMC: 130507. DOI: 10.1073/pnas.182407599. View

11.

Chang S, DePinho R . Telomerase extracurricular activities. Proc Natl Acad Sci U S A. 2002; 99(20):12520-2. PMC: 130491. DOI: 10.1073/pnas.212514699. View

12.

Pollock P, Harper U, Hansen K, Yudt L, Stark M, Robbins C . High frequency of BRAF mutations in nevi. Nat Genet. 2002; 33(1):19-20. DOI: 10.1038/ng1054. View

13.

Kannan K, Sharpless N, Xu J, OHagan R, Bosenberg M, Chin L . Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A. 2003; 100(3):1221-5. PMC: 298754. DOI: 10.1073/pnas.0336397100. View

14.

Dajee M, Lazarov M, Zhang J, Cai T, Green C, Russell A . NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 2003; 421(6923):639-43. DOI: 10.1038/nature01283. View

15.

Hayward N . Genetics of melanoma predisposition. Oncogene. 2003; 22(20):3053-62. DOI: 10.1038/sj.onc.1206445. View

16.

Wu H, Goel V, Haluska F . PTEN signaling pathways in melanoma. Oncogene. 2003; 22(20):3113-22. DOI: 10.1038/sj.onc.1206451. View

17.

Sharpless N, Kannan K, Xu J, Bosenberg M, Chin L . Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene. 2003; 22(32):5055-9. DOI: 10.1038/sj.onc.1206809. View

18.

Tsao H, Goel V, Wu H, Yang G, Haluska F . Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004; 122(2):337-41. PMC: 2586668. DOI: 10.1046/j.0022-202X.2004.22243.x. View

19.

Schaffer J, Rigel D, Kopf A, Bolognia J . Cutaneous melanoma--past, present, and future. J Am Acad Dermatol. 2004; 51(1 Suppl):S65-9. DOI: 10.1016/j.jaad.2004.01.030. View

20.

Brookes S, Rowe J, Gutierrez Del Arroyo A, Bond J, Peters G . Contribution of p16(INK4a) to replicative senescence of human fibroblasts. Exp Cell Res. 2004; 298(2):549-59. DOI: 10.1016/j.yexcr.2004.04.035. View